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Abstract. A child with myosit is ossificans progressiva was 
t reated for 8 years with e thane- l -hydroxy- l , l -d iphospho-  
nate (EHDP)  30-40 mg/kg per  day. Latter ly  he com- 
pla ined of severe, progressive bone and jo int  pain which 
made standing and walking almost impossible.  A radio-  
graphic skeletal  survey showed diffuse r icket- l ike lesions. 
Wi thdrawal  of EHDP therapy produced substantial  im- 
provement  in his general  condit ion as well as in the radio-  
graphic appearance of the bones. Mult ip le exostoses were 
observed in this case and, part icular ly  those around the 
knees, presented a pecul iar  morphology.  This supports the 
theory that exostoses or iginate from a defect of meta-  
physeal  model l ing. 
E thane- l -hydroxy- l , l -d iphosphonate  (EHDP)  was the 
first d iphosphonate  obe used in clinical pract ice to inhibit  
osteoclastic resorpt ion and the process of calcif ication [1]. 
In this child with myosit is ossificans progressiva it had 
been admin is tered over a long per iod  to counteract  the 
progressive ossif ication caused by the disease. The clinical 
and radiographic  evolut ion of the case i l lustrate the side 
effects of this therapy  in myosit is ossificans progressiva 
and the care which is necessary when bone remodel l ing in- 
hibitors are used in chi ldren. 
Case report 
In April 1983, a 5-year-old boy complained ofpain in the right knee 
which was followed by the appearance of a small hard nodule over 
the lateral aspect of the joint. No congenital or hereditary diseases 
were present in the family history and no relevant disease had been 
reported in the first 5 years of life. Shortly afterwards a localized 
swelling appeared in the right sternocleidomastoid muscle. Initially 
the lesion was hot and tender, but after a few days the inflammation 
subsided, leaving a smaller ossified lesion in a retracted muscle. 
After 5 months the child was found to have torticollis. A muscle bi- 
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opsy performed elsewhere did not show any relevant pathological 
change. Treatment with steroid was started and continued for sev- 
eral months. 
One and half years later a large soft tissue swelling appeared in
the shoulder girdle and followed a course similar to the lesion in the 
sternodeidomastoid muscle. The child was admitted to another hos- 
pital 1 month later. Laboratory tests howed that inflammatory pa- 
rameters, erum calcium and phosphate, alkaline phosphatase and 
muscle enzymes were normal. Electromyography was also normal. 
A muscle biopsy was consistent with myositis ossificans progressiva. 
Therapy was started with ethane-l-hydroxyd,l-diphosphonate 
(EHDP) 30 mg/kg per day. Over the following months new lesions 
occurred periodically and spread iffusely m the cervical and dorsal 
regions and sacrum. Limitation of movement developed inthe major 
joints of the limbs, with the exception of the knees. 
Two and half years after the appearance of the first signs, diffuse 
rigidity and widespread caldficafion of soft tissue were present de- 
spite continuous therapy with EHDR Repeated laboratory tests 
showed a normal evel of alkaline phosphatase. The dose of EHDP 
was increased to 40 mg/kg per day and low-dose prednisone, piroxi- 
cam and androgens were added. Physiotherapy was performed 
throughout this time in an attempt to prevent joint contractures. In 
spite of the therapy ossification of muscles, tendons and fascias pro- 
gressed with increasing limitation of movement and contractures of 
joints in the following 3 years. 
The patient was first admitted to the Paediatric Clinic of the 
University of Pavia at the age of 13 years, after having taken EHDP 
continuously for 8 years. Physical examination showed severely re- 
duced mobility of shoulders, elbows, wrists, hips and ankles; the 
neck was flexed and ankylosed; the dorsal spine had a severe ky- 
phoscoliosis and widespread subcutaneous calcifications were pre- 
sent in the right scapular region. Muscles were diffusely wasted. A
short, valgus big toe was present in both feet. The child referred 
severe pain to joints and bones; walking and standing were almost 
impossible. The results of routine laboratory tests were normal, as 
were those on serum muscle enzymes. Bone metabolism parame- 
ters were as follows: calcium 9,8 mg/dl [normal range (NR) 9-11]; 
phosphate 5.0 mg/dl (NR 3-5). Alkaline phosphatase 1942 (in- 
creased) fundal examination was normal. Functional tests of respir- 
ation revealed severe restrictive changes. Radiography showed 
frank ricket-like lesions (see below); therefore therapy with diphos- 
phonates was withdrawn. 
Two months later the patient's general condition had improved, 
the pain had disappeared and he could walk without help. Stiffness 
and joint contractures were unchanged, but the absence of pain had 
improved his ability in daily activities and he moved more confident- 
ly. Results of laboratory tests were as follows: calcium 9.3 mg/dl (NR 
%11); phosphate 6.8 mg/dl (NR 3-5); alkaline phosphatase 1849 (in- 
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creased); osteocalcin 36.3mg/ml (NR 2.0-8.5); vitamin D3 
5.2 mg/ml (NR 16.0-74.0); procollagen I > 500 ng/ml (NR 50.0- 
170.0); procollagen II1200 U/ml (NR 0.3-0.8). 
Radiographic f ndings 
Skeletal radiographs performed at different times were available: 
1. When the child was 12 years old after 7years of therapy with 
diphosphonates 
2. At 13 years, when the decision to withdraw therapy was taken 
3. Three months after withdrawal of diphosphonates 
1. At 12 years epiphyseal nd metaphyseal osteopenia of the 
proximal tibia and distal femur was evident. The growth plate was 
regular and of normal thickness. A thin denser band was present in 
the upper part of the metaphysis just below the growth plate (corre- 
sponding to the area of primary metaphyseal trabeculae). The proxi- 
mal tibial metaphyses onthe medial side showed bony beaks imilar 
to exostoses; a similar formation was present in the right distal fem- 
oral metaphysis. Small exostoses were present on both sides of the 
left distal femoral metaphysis (Fig. i a). 
2. At 13 years more severe osteopenia was evident in the grow- 
ing metaphyses and there was, furthermore, a very broad band of 
radiolucency (osteoid) between the growth plate and metaphysis 
such as is usually seen in severe rickets. Within the metaphyseal 
Fig. 1. a Radiograph at the age of 12 (after 7 years of EHDP treatment). Note 
the epiphyseal nd metaphyseal osteopenia; denser metaphyseal band at the 
site of primary metaphyseal trabeculae; xostoses in both tibiae and the right 
femur; and small exostoses onboth sides of the right femur, where coning of 
the metaphysis starts 
b Radiograph at the age of 13 years (after 8 years of EHDP treatment). There 
is severe osteopenia and a thick, radiolucent band below the growth plate as 
observed in rickets; the contours of the epiphyses and metaphyses are blurred 
and irregular; the small exostoses of the right femur are no longer evident 
c Radiograph 3 months after withdrawal of EHDP. The metaphyseal r diolu- 
cent band has disappeared and there is increased bone density in both epi- 
physes and metaphyses; in the left femur the two small exostoses have reap- 
peared 
Fig.2a, b. Radiographs at the age of 13 years (after 8 years of EHDP treat- 
ment). There is osteopenia and ricket-like changes of the distal tibial meta- 
physis; inside the thick radiolucent band an irregular and dense calcification is 
present; note the exostosis of the tarsal bone 
band of osteoid dense areas of calcification were present (Fig. lb); 
the contours of the epiphyseal ossification centres and the borders 
of the metaphyses were blurred and irregular. Cloaking of tibial and 
fibular shafts was also evident. Both proximal tibial metaphyses 
had a cylindrical shape with the lower angle corresponding tothe 
base of the exostoses. The small exostoses inthe left femur were no 
longer evident (Fig. I b). Similar changes were evident in both 
proximal metaphyses of the humeri, distal radii, proximal and distal 
femora, chondrosternal junctions and vertebral end plates; they 
were not present in the metaphyses of the tubular bones of the 
hands and feet. Osteopenia was also evident in the shafts of the 
long bones, the carpal and tarsal bones (Fig.2) and the epiphyses of 
long bones. The skull, facial bones, clavicles, ribs and pelvic bones 
showed mineral density within the normal range. A taIar beak was 
present in both talar bones (Fig. 2). The first metatarsals were short 
and stubby and the proximal phalanges were divided into two large 
triangular bones resulting in valgus deviation (Fig. 3). Other find- 
ings consistent with myositis ossificans progressiva were the wide- 
spread calcification of the nuchal igament (Fig.4 a), dorsal and 
lumbar paravertebral muscles (Fig. 4 b), and interspinous and inter- 
transverse ligaments of the cervical spine. The apophyseal joints 
between C2 and C7 were fused (Fig.4a). The seventh and the 
eighth left ribs showed a sharp angulation in their second portion 
and were fused in a large, irregular bony structure abutting below 
the muscles. 
3. At follow-up 3 months after withdrawal of diphosphonates a 
dramatic disappearance of the rnetaphyseal osteoid border was evi- 
dent. In its place bone denser than normal was detectable and the 
zone of provisional calcification was sharp and well defined. Both 
proximal tibial epiphyses presented a double bony contour, instead 
of the blurred and irregular border previously observed. Above the 
left distal femoral metaphysis the two small exostoses were again 
evident (Fig. 1 c). Osteopenia was also no longer present in the other 
bones. 
Discussion 
Skeletal malformations and abnormalities of the big toes 
are present in 95 % of cases of myositis ossificans pro- 
gressiva [2] and are therefore of great diagnostic value. 
Four subtypes of malformations of the big toe have been 
described [3]: those observed in the case reported here fit 
type 1, but with the peculiar feature (previously unre- 
ported) that the single proximal phalanx was divided into 
two large triangular bones. 
EHDP has been used in the treatment of myositis ossi- 
ficans progressiva to prevent mineralization ofareas of ac- 
tive myositis or remineralization after surgical removal of 
ectopic ossifications [4-6]. Controversial findings regard- 
ing the efficacy of this therapy have been reported [2, 7] 
and variability of results has been ascribed to the activity 
of the disease and to the plasma level of diphosphonate, 
which in turn depends on the oral dosage and intestinal 
absorption [8]. Doses which vary from a minimum of 
5 mg/kg per day to a maximum of 40 mg/kg per day have 
Fig.3. Radiograph at the age of 13 years (after 8 years of EHDP 
treatment). Note the dense metaphyseal band of the first metatarsal 
and the widening of the growth plate; the proximal phalanx is formed 
by two triangular bones and the toe is deviated in valgus 
Fig.4a, b. Radiographs at the age of 13 years (after 8years of 
EHDP treatment), a Ossification of the nuchal ligament (arrows) 
and interspinous and intertransverse ligaments of the cervical spine. 
b Ossification of the dorsal and lumbar paravertebral muscles 
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been used [7]. Complications of diphosphonate herapy 
have been reported by Smith et al. [8] in a boy treated with 
EHDP 10 mg/kg per day for 2 years and by Rogers et al. 
[9] in a 3-year-old boy treated with 37 mg/kg per day. The 
former showed widened growth plates, dense metaphyses 
and pathological decalcification, while bone pain and 
muscle weakness were absent. The latter complained of 
hypotonia, weakness and a shuffling, unsteady gait, and 
radiographs howed generalized osteopenia, transverse 
radiolucent bands in the metaphyses ofthe long bones and 
widening of the growth plates. Weiss et al. [10], in another 
patient, documented a decreased bone turnover by radio- 
isotope measurement. 
By comparison, other diphosphonates, namely dichlo- 
ro-methylene diphosphonate and the nitrogen-containing 
diphosphonates, are known to be potent inhibitors of 
bone resorption but are less effective inhibitors of min- 
eralization. The effects of the latter on the growing skele- 
ton are band-like metaphyseal sclerosis and concentric 
epiphyseal nd apophyseal sclerosis associated with meta- 
physeal undertubulation f long bones [11]. 
Our patient, after a very long period of treatment with 
30-40mg/kg per day EHDR developed osteopenia, 
widening of the growth plates and a dense metaphyseal 
band as reported by Smith et al. [8]. These features pro- 
gressed to more severe changes of the metaphyses, asdes 
cribed in the case of Rogers et al. [2]. These radiographic 
lesions were accompanied by weakness, hypotonia nd 
difficulty of gait. There is little doubt hat all these are con- 
sequences of high-dose EHDP therapy, since withdrawal 
of therapy was followed by disappearance of all symptoms 
and normalization of the radiographic appearances. 
The variable radiographic features secondary to 
EHDP treatment can be explained by the mechanism of 
action of the drug, as shown in animal studies [12]. The 
dense metaphyseal band, due to arrested resorption of 
primary metaphyseal trabeculae, together with the cylin- 
drical shape of the proximal tibial metaphyses (failure of 
conization), indicate an arrest of the remodelling process. 
This is followed by complete inhibition of calcification, 
with the transverse band of radiolucency corresponding to
accumulation in the metaphyses of a mass of osteoid 
tissue. The block on calcification is maintained as long as 
the plasma level of EHDP remains above a threshold 
value [12]. If this falls, as a consequence of irregularities in
the oral intake or intestinal absorption, focal calcification 
of the osteoid mass occurs, as was evident in our case. 
Exostoses were another peculiar feature of our case. It 
has already been observed that bony beaks, more fre- 
quent around the knee, are often associated with myositis 
ossificans progressiva treated with bone remodelling in- 
hibitors [3]. In the case reported here the multiple exos- 
toses have a peculiar morphology, especially those on the 
medial side of both tibiae, which supports the view that 
their formation is due to the arrest of metaphyseal modell- 
ing. Moreover adiographic monitoring of the knees after 
EHDP withdrawal showed the appearance of two small, 
new exostoses in the left femoral metaphysis where struc- 
tural anomalies were more severe. This finding supports 
the theory of the origin of exostoses formulated in a study 
on multiple exostosis disease [13]. 
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The osteopenia observed in all the reported cases can 
be interpreted as osteomalacia and histological confirma- 
tion of this interpretation is given by case 3 of Smith et al. 
[8]. It has been stated that complications of EHDP treat- 
ment in growing children are different from rickets [9]. 
The mechanism of interference of EHDP with vitamin D 
metabolism remains obscure; however, it cannot be over- 
emphasized that the arrest of bone remodell ing and in- 
hibition of calcification are both common aspects of rick- 
ets and high-dose EHDP therapy. Moreover the weak- 
ness, hypotonia nd difficulty of gait present in our case, as 
well as in that reported by Rogers et al. [9] support the 
view of a relative disturbance of calcium and phosphate 
homeostasis. 
The results of laboratory tests in our case support he 
hypothesis of an interference by EHDP with vitamin D 
metabolism, since the value of the latter was much lower 
than normal. 
The occurrence of these severe complications in chil- 
dren treated for myositis ossificans progressiva casts seri- 
ous doubt on EHDP therapy. It is not simply a question of 
overdose, because to prevent mineralization of foci of 
active myositis it is necessary to reach plasma levels of 
EHDP at which the active growth plate cartilage and 
metaphyses are also affected. 
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